Tumour mutational burden and survival with molecularly matched therapy
The impact of tumour mutational burden (TMB) on outcome with molecularly matched therapy is unknown. Higher TMB could predict resistance to molecularly matched therapy through co-occurring driver mutations.
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
September 2023
|
| In: |
European journal of cancer
Year: 2023, Jahrgang: 190, Pages: 1-10 |
| ISSN: | 1879-0852 |
| DOI: | 10.1016/j.ejca.2023.05.013 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.ejca.2023.05.013 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0959804923002538 |
| Verfasserangaben: | Till de Bortoli, Manuela Benary, Peter Horak, Mario Lamping, Sebastian Stintzing, Ingeborg Tinhofer, Serge Leyvraz, Reinhold Schäfer, Frederick Klauschen, Ulrich Keller, Albrecht Stenzinger, Stefan Fröhling, Razelle Kurzrock, Ulrich Keilholz, Damian T. Rieke, Ivan Jelas |
| Zusammenfassung: | The impact of tumour mutational burden (TMB) on outcome with molecularly matched therapy is unknown. Higher TMB could predict resistance to molecularly matched therapy through co-occurring driver mutations. |
|---|---|
| Beschreibung: | Online veröffentlicht am 4. August 2023 Gesehen am 12.12.2023 |
| Beschreibung: | Online Resource |
| ISSN: | 1879-0852 |
| DOI: | 10.1016/j.ejca.2023.05.013 |